Pericytes: A Double-Edged Sword in Cancer Therapy

References

• Jain RK . Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J. Clin. Oncol.31(17), 2205–2218 (2013).
   PubMed Web of Science ®Google Scholar
• Jain RK . A new target for tumor therapy. N. Engl. J. Med.360(25), 2669–2671 (2009).
   PubMed Web of Science ®Google Scholar
• Xian X , HakanssonJ, StahlbergAet al. Pericytes limit tumor cell metastasis. J. Clin. Invest.116(3), 642–651 (2006).
   PubMed Web of Science ®Google Scholar
• Cooke VG , LebleuVS, KeskinDet al. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell21(1), 66–81 (2012).
   PubMed Web of Science ®Google Scholar
• Bergers G , HanahanD. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer8(8), 592–603 (2008).
   PubMed Web of Science ®Google Scholar
• Eberhard A , KahlertS, GoedeV, HemmerleinB, PlateKH, AugustinHG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res.60(5), 1388–1393 (2000).
   PubMed Web of Science ®Google Scholar
• Nagy JA , ChangSH, ShihSC, DvorakAM, DvorakHF. Heterogeneity of the tumor vasculature. Semin. Thromb. Hemost.36(3), 321–331 (2010).
   PubMed Web of Science ®Google Scholar
• Mancuso MR , DavisR, NorbergSMet al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest.116(10), 2610–2621 (2006).
   PubMed Web of Science ®Google Scholar
• Khasraw M , AmeratungaM, GrommesC. Bevacizumab for the treatment of high-grade glioma: an update after Phase III trials. Expert Opin. Biol. Ther.14(5), 729–740 (2014).
   PubMed Web of Science ®Google Scholar
• Paulsson J , SjoblomT, MickePet al. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am. J. Pathol.175(1), 334–341 (2009).
   PubMed Web of Science ®Google Scholar
• Hagglof C , HammarstenP, JosefssonAet al. Stromal PDGFRbeta expression in prostate tumors and non-malignant prostate tissue predicts prostate cancer survival. PLoS ONE5(5), e10747 (2010).
   PubMed Web of Science ®Google Scholar
• Furuhashi M , SjoblomT, AbramssonAet al. Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. Cancer Res.64(8), 2725–2733 (2004).
   PubMed Web of Science ®Google Scholar
• Ruan J , LuoM, WangCet al. Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood121(26), 5192–5202 (2013).
   PubMed Web of Science ®Google Scholar
• Pietras K , PahlerJ, BergersG, HanahanD. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med.5(1), e19 (2008).
   PubMed Web of Science ®Google Scholar
• Tsao AS , LiuS, FujimotoJet al. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J. Thorac. Oncol.6(12), 2104–2111 (2011).
   PubMed Web of Science ®Google Scholar
• Wen PY , YungWK, LambornKRet al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99–08. Clin. Cancer Res.12(16), 4899–4907 (2006).
   PubMed Web of Science ®Google Scholar
• Raymond E , BrandesAA, DittrichCet al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J. Clin. Oncol.26(28), 4659–4665 (2008).
   PubMed Web of Science ®Google Scholar
• Coleman RL , BroaddusRR, BodurkaDCet al. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol. Oncol.101(1), 126–131 (2006).
   PubMed Web of Science ®Google Scholar
• Pietras K , HanahanD. A multitargeted, metronomic, and maximum-tolerated dose “chemo-switch” regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J. Clin. Oncol.23(5), 939–952 (2005).
   PubMed Web of Science ®Google Scholar
• Kuhnert F , TamBY, SenninoBet al. Soluble receptor-mediated selective inhibition of VEGFR and PDGFRbeta signaling during physiologic and tumor angiogenesis. Proc. Natl Acad. Sci. USA105(29), 10185–10190 (2008).
   PubMed Web of Science ®Google Scholar
• Lu C , KamatAA, LinYGet al. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin. Cancer Res.13(14), 4209–4217 (2007).
   PubMed Web of Science ®Google Scholar
• Klosowska-Wardega A , HasumiY, BurmakinMet al. Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma. PLoS ONE4(12), e8149 (2009).
   PubMed Web of Science ®Google Scholar
• Taeger J , MoserC, HellerbrandCet al. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol. Cancer Ther.10(11), 2157–2167 (2011).
   PubMed Web of Science ®Google Scholar
• Raymond E , DahanL, RaoulJLet al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med.364(6), 501–513 (2011).
   PubMed Web of Science ®Google Scholar
• Demetri GD , Van OosteromAT, GarrettCRet al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet368(9544), 1329–1338 (2006).
   PubMed Web of Science ®Google Scholar
• Koeberle D , MontemurroM, SamarasPet al. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter Phase II trial (SAKK 77/06). Oncologist15(3), 285–292 (2010).
   PubMed Web of Science ®Google Scholar
• Grothey A , Van CutsemE, SobreroAet al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet381(9863), 303–312 (2013).
   PubMed Web of Science ®Google Scholar
• Blumenschein GR, Jr., GatzemeierU, FossellaFet al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J. Clin. Oncol.27(26), 4274–4280 (2009).
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK , JohnsonP, KnoxJJet al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA304(19), 2154–2160 (2010).
   PubMed Web of Science ®Google Scholar
• Sennino B . Two is better than one: benefits of VEGF and PDGF inhibition in ovarian cancer. Cancer Biol. Ther.9(3), 183–185 (2010).
   PubMed Web of Science ®Google Scholar
• Welen K , JennbackenK, TesanT, DamberJE. Pericyte coverage decreases invasion of tumour cells into blood vessels in prostate cancer xenografts. Prostate cancer and prostatic diseases.12(1), 41–46 (2009).
   PubMed Web of Science ®Google Scholar
• Yonenaga Y , MoriA, OnoderaHet al. Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients. Oncolog.69(2), 159–166 (2005).
   Google Scholar
• Qian CN , HuangD, WondergemB, TehBT. Complexity of tumor vasculature in clear cell renal cell carcinoma. Cancer115(10 Suppl.), 2282–2289 (2009).
   PubMed Web of Science ®Google Scholar
• McCarty MF , SomcioRJ, StoeltzingOet al. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. J. Clin. Invest.117(8), 2114–2122 (2007).
   PubMed Web of Science ®Google Scholar
• Banfi A , Von DegenfeldG, Gianni-BarreraRet al. Therapeutic angiogenesis due to balanced single-vector delivery of VEGF and PDGF-BB. FASEB J.26(6), 2486–2497 (2012).
   PubMed Web of Science ®Google Scholar
• Chen RR , SilvaEA, YuenWW, MooneyDJ. Spatio-temporal VEGF and PDGF delivery patterns blood vessel formation and maturation. Pharm. Res.24(2), 258–264 (2007).
   PubMed Web of Science ®Google Scholar
• Greenberg JI , ShieldsDJ, BarillasSGet al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature456(7223), 809–813 (2008).
   PubMed Web of Science ®Google Scholar
• Lederle W , LindeN, HeuselJet al. Platelet-derived growth factor-B normalizes micromorphology and vessel function in vascular endothelial growth factor-A-induced squamous cell carcinomas. Am. J. Pathol.176(2), 981–994 (2010).
   PubMed Web of Science ®Google Scholar
• Korpisalo P , KarvinenH, RissanenTTet al. Vascular endothelial growth factor-A and platelet-derived growth factor-B combination gene therapy prolongs angiogenic effects via recruitment of interstitial mononuclear cells and paracrine effects rather than improved pericyte coverage of angiogenic vessels. Circ. Res.103(10), 1092–1099 (2008).
   PubMed Web of Science ®Google Scholar
• Fuxe J , TabruynS, ColtonKet al. Pericyte requirement for anti-leak action of angiopoietin-1 and vascular remodeling in sustained inflammation. Am. J. Pathol.178(6), 2897–2909 (2011).
   PubMed Web of Science ®Google Scholar
• Chae SS , KamounWS, FarrarCTet al. Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin. Cancer Res.16(14), 3618–3627 (2010).
   PubMed Web of Science ®Google Scholar
• Falcon BL , HashizumeH, KoumoutsakosPet al. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am. J. Pathol.175(5), 2159–2170 (2009).
   PubMed Web of Science ®Google Scholar
• Nasarre P , ThomasM, KruseKet al. Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res.69(4), 1324–1333 (2009).
   PubMed Web of Science ®Google Scholar
• Huang Y , SongN, DingYet al. Pulmonary vascular destabilization in the premetastatic phase facilitates lung metastasis. Cancer Res.69(19), 7529–7537 (2009).
   PubMed Web of Science ®Google Scholar